GSK to build flagship Cambridge R&D centre in £400m move 2026

Key Points

• GSK will establish a new 300,000 sq ft flagship global R&D centre on the Cambridge Biomedical Campus, UK.
• The company will invest £400 million over three years to support the move and related upgrades.
• More than 1,000 scientists will be based at the new Cambridge site, with a phased relocation from Stevenage by 2029.
• GSK will vacate its historic R&D hub in Stevenage, Hertfordshire, and upgrade its Ware laboratories to create an integrated drug development and scale-up capability.
• The Cambridge centre will focus on Oncology, Respiratory, Hepatology, Vaccines and HIV research, with state-of-the-art, tech-enabled labs.
• The site, being developed by Prologis on Discovery Drive, sits within the UK’s life sciences “Golden Triangle” and one of Europe’s largest biomedical campuses.
• GSK’s CEO Luke Miels said the move will accelerate R&D and deliver new, competitive products while integrating GSK into a leading global ecosystem.
• The announcement coincides with GSK’s Q2 2026 results and a wider programme targeting £1.9 billion of annual savings by 2029.

Cambridge (Cambridge Tribune) July 28, 2026 – GSK has confirmed plans to build a new flagship global research and development centre on the Cambridge Biomedical Campus, marking a £400 million investment in UK life sciences and a strategic shift away from its long-standing Stevenage R&D hub. The pharmaceutical group said the 300,000 square foot facility will house more than 1,000 scientists and become the home of its UK R&D operations, with a phased move of staff from Stevenage to be completed by 2029.

What is GSK planning for its new Cambridge R&D centre?

GSK’s new centre will be located on Discovery Drive within the Cambridge Biomedical Campus, a site described by the company as being in the heart of the UK’s life sciences “Golden Triangle”. The facility, currently in development by property partner Prologis, is planned across three interconnected buildings – 2000, 3000 and 4000 Discovery Drive – and will feature state-of-the-art, technology-enabled laboratories and infrastructure.

As reported by the GSK press office, the new site will support research in the company’s core therapeutic areas: Oncology, Respiratory, Hepatology, Vaccines and HIV. The campus environment is intended to provide GSK scientists with direct access to a dense ecosystem of biomedical research, patient care and academia, enabling translational research that bridges laboratory science and clinical practice.

How will the Cambridge move affect GSK’s Stevenage and Ware sites?

Under the new plans, GSK will vacate its R&D site in Stevenage, Hertfordshire, with a phased relocation of employees to Cambridge and Ware by 2029. Around 1,800 staff currently work at the Stevenage R&D hub, but the company has indicated that the new Cambridge centre will accommodate more than 1,000 scientists.

Alongside the Cambridge move, GSK will upgrade its existing R&D laboratories at Ware in Hertfordshire and transfer some employees there to create a fully integrated drug development and commercial manufacturing scale-up capability. The group is spending £400 million over the next three years to fund these changes, which include the new Cambridge build, the Ware upgrades and the relocation programme.

Why is GSK relocating R&D from Stevenage to Cambridge?

GSK’s chief executive Luke Miels said the investment will accelerate the company’s R&D and help deliver new, competitive products. “It integrates GSK further into one of the world’s leading centres of knowledge and demonstrates the attractiveness of the UK’s life sciences ecosystem,” Miels added, according to reports quoting the company’s statements.

As noted by the Financial Times, the relocation comes as Miels seeks to strengthen GSK’s pipeline of new medicines, including by launching more than 20 phase III trials in 2026. The Cambridge Biomedical Campus is one of the largest biomedical campuses in Europe and hosts major academic and clinical institutions, offering proximity to partners such as the University of Cambridge, Cambridge University Hospitals and other research organisations.

What does the investment mean for UK life sciences?

The £400 million commitment reinforces GSK’s footprint in the UK, where its global headquarters remains in London. As reported by multiple outlets, the move is framed as a catalyst for collaboration and faster medicine development, integrating GSK more deeply with leading academic institutions and scientific organisations including the University of Oxford, King’s College London, Imperial College, the University of Manchester, Wellcome and the Crick Institute.

London Loves Business observed that GSK’s Cambridge move highlights the high cost of staying competitive in global drug development, with access to talent, infrastructure and collaborative networks seen as critical. The Economic Times of India noted that the investment forms part of a broader push under Miels to develop medicines faster while facing upcoming patent expiries.

How does this fit with GSK’s Q2 2026 results and cost programme?

The R&D announcement was made alongside GSK’s second-quarter 2026 results, in which the company reported turnover of £8.4 billion, up 5 per cent year on year. In parallel, GSK outlined a three-year programme targeting £1.9 billion of annual savings by 2029 to fund investment in its late-stage portfolio and simplify the organisation.

As the Financial Times reported, the Cambridge hub forms part of a wider strategy to bolster pipelines of new medicines while managing cost pressures and patent cliffs. Shares rose after the company exceeded profit expectations and set out the savings plan, according to market coverage.

What are the timelines for the Cambridge campus build and staff move?

GSK has indicated a phased move for employees from Stevenage to Cambridge and Ware, to be completed by 2029. The new 300,000 sq ft site is already in development by Prologis, with planning and construction progressing on the Discovery Drive plots within the wider Cambridge Biomedical Campus.

The company has not provided a detailed month-by-month timetable, but the three-year investment window and the 2029 completion target for the Stevenage exit imply a multi-stage transition of teams, equipment and laboratory functions.

Background of the Cambridge R&D development

GSK has maintained a significant UK R&D presence for decades, with Stevenage emerging as a major research hub for the company. The Cambridge Biomedical Campus has grown in recent years into one of Europe’s largest concentrations of biomedical research, clinical care and life sciences companies, attracting investment from global pharma and biotech firms.

The decision to establish a new flagship centre in Cambridge follows a strategic review of GSK’s R&D footprint under new leadership. By moving into a purpose-built, tech-enabled facility on the campus, GSK aims to position its UK scientists closer to academic collaborators, clinical trial infrastructure and specialist talent pools, while consolidating functions across Stevenage and Ware into a more integrated model.

Prediction: How this development could affect scientists, patients and the UK sector

For scientists and R&D staff, the Cambridge move is likely to reshape day-to-day work by placing teams in a more collaborative, campus-based environment with shared access to academic and clinical partners. Some Stevenage-based roles will transfer to Cambridge or Ware, while others may be affected by the consolidation and the wider £1.9 billion savings programme.

For patients, the intended effect is faster translation of laboratory discoveries into clinical trials and, ultimately, new treatments in areas such as cancer, respiratory disease, liver disease, vaccines and HIV. If the Cambridge ecosystem delivers on its promise of closer academia–industry links, GSK’s pipeline could benefit from earlier feedback loops between bench research and patient data.

For the UK life sciences sector, GSK’s £400 million investment signals continued confidence in the “Golden Triangle” corridor and may encourage further clustering of R&D activity in Cambridge and surrounding regions. However, the parallel cost-saving drive and site closures also underline the competitive pressures facing large pharma, meaning the long-term impact will depend on how effectively the new centre accelerates drug development and delivers approvals.